Graybug Vision 股票定于3月20日星期一反向拆分（纳斯达克股票代码：GRAY）

Graybug Vision, Inc. (NASDAQ:GRAY – Get Rating) shares are set to reverse split on the morning of Monday, March 20th. The 1-14 reverse split was announced on Monday, March 20th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, March 20th.

Graybug Vision Price Performance

Shares of NASDAQ:GRAY opened at $0.44 on Friday. The company's 50-day moving average price is $0.63 and its two-hundred day moving average price is $0.77. Graybug Vision has a one year low of $0.44 and a one year high of $1.58. The stock has a market capitalization of $9.69 million, a PE ratio of -0.25 and a beta of 1.20.

Institutional Investors Weigh In On Graybug Vision

Institutional investors and hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC raised its holdings in shares of Graybug Vision by 221.3% in the 1st quarter. Renaissance Technologies LLC now owns 35,341 shares of the company's stock valued at $43,000 after purchasing an additional 24,341 shares during the period. Bank of New York Mellon Corp bought a new stake in shares of Graybug Vision in the 1st quarter valued at about $125,000. Vanguard Group Inc. raised its holdings in shares of Graybug Vision by 5.5% in the 1st quarter. Vanguard Group Inc. now owns 455,572 shares of the company's stock valued at $561,000 after purchasing an additional 23,846 shares during the period. Finally, BML Capital Management LLC bought a new stake in shares of Graybug Vision in the 4th quarter valued at about $618,000. 49.94% of the stock is owned by institutional investors.

About Graybug Vision

(Get Rating)

Graybug Vision, Inc, a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.

Recommended Stories

• Get a free copy of the StockNews.com research report on Graybug Vision (GRAY)
• This Small Tech With Big Growth Prospects Is Nearing A Buy Point
• Don't Chase FedEx Higher, Wait For The Pullback
• 3 Stocks For A Defensive Tech Portfolio
• Milk the Dividends on These 3 Cash Cows
• Europe Raises Interest Rates, Should the Fed Follow?

Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.